Therapeutics News

VANCOUVER, British Columbia — The International League of Dermatological Societies’ 23rd World Congress of Dermatology is underway here, and Healio.com/Dermatology will provide coverage of the meeting starting today.

The American Academy of Dermatology announced that more than 18,500 people attended its annual meeting, held from March 20-24 in San Francisco.

Healio.com/Dermatology will provide coverage of the American Academy of Dermatology Annual Meeting in San Francisco beginning Friday.

In a literature review, the National Psoriasis Foundation developed treatment recommendations for four nail psoriasis possibilities.

Amgen and AstraZeneca have announced that AMAGINE-2, a multi-arm, phase 3 trial to determine the efficacy of brodalumab in patients with moderate-to-severe plaque psoriasis, met its primary endpoints compared with ustekinumab and placebo at week 12.

Regeneron Pharmaceuticals and Sanofi announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to dupilumab for adults with moderate-to-severe atopic dermatitis who are not adequately controlled with topical prescription therapy or for whom such treatments are not appropriate.

In adults with acute bacterial skin and skin-structure infection, weekly dalbavancin was found to be noninferior to daily vancomycin, according to researchers.

Novartis has announced that the Dermatologic and Ophthalmic Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to support the approval of AIN457 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.

AbbVie has announced results from its PIONEER II study demonstrating the effectiveness of Humira in reducing symptoms of moderate-to-severe hidradenitis suppurativa.

The combination of intralesional cryosurgery followed by the application of topical silicone gel sheeting was useful in the treatment of refractory keloids, according to study findings.